Tiramin
Thyroid cytamin — Khavinson-school organ peptide fraction, oral tablet
Tiramin (Thyroid cytamin — Khavinson-school organ peptide fraction, oral tablet) is a longevity & bioregulators research compound. A Khavinson-school polypeptide fraction from animal thyroid, 155mg per tablet. The class premise is tissue specificity — an extract of organ X acting on organ X — argued from organotypic explant work at nanogram concentrations. Four papers carry that claim across nine tissues: brain cortex, subcortical structures, pineal, liver, thymus, heart, lung, prostate, pancreas and cartilage. None of them used thyroid.
Tiramin quick facts
| Route | Oral |
| Frequency | Not established · Not established |
| Half-life | Not characterized — no analytical method for this preparation has been published |
| Forms | Oral |
| Evidence level | No published study of this product. The literature belongs to the parenteral extracts and the synthetic peptides of the same school. |
The thyroid is a closed feedback loop with three routine numbers in it, so a real effect would show on TSH within about six weeks — which makes this the organ where a positive result would have been easiest to demonstrate, and nobody has demonstrated one. A PubMed search for the product's name on 8 September 2026 returned two records, neither about it. The safety question specific to an unassayed animal thyroid preparation is hormone content: when a comparable glandular category was tested by chromatography, 9 of 10 products contained detectable T3 and 5 of 10 contained T4, some at doses overlapping ordinary hypothyroidism treatment.
How Tiramin works
A Khavinson-school polypeptide fraction from animal thyroid, 155mg per tablet. The class premise is tissue specificity — an extract of organ X acting on organ X — argued from organotypic explant work at nanogram concentrations. Four papers carry that claim across nine tissues: brain cortex, subcortical structures, pineal, liver, thymus, heart, lung, prostate, pancreas and cartilage. None of them used thyroid.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Tiramin
Buy Tiramin at RUPharma →The evidence for Tiramin
Graded by what exists behind each claim.
✅ Clinically validated
- None, and the search returned two false positives worth naming so it can be repeated: a cervical HPV detection study and a 1976 urticaria provocation test, both matched on a lexically similar word (PubTator3, 8 September 2026).
📊 Correlative data
- The tissue-specificity claim this product line rests on has never been tested on thyroid. Four organotypic-culture papers carry it, across nine tissues — brain cortex, subcortical, pineal, liver, thymus, heart, lung, prostate, pancreas and cartilage (Khavinson 2001, Khavinson 2002, Zakutskii 2006, Ryzhak 2015). Thyroid appears in none of them.
🧪 Theoretical / extrapolated
- The thyroid axis is a closed feedback loop measured in tens of millions of people a year. Of all seventeen organs on this shelf it is the one where a real effect would be easiest to demonstrate — TSH moves within about six weeks — and nobody has demonstrated it.
- The hormone-content question is the one that matters. When a comparable glandular supplement category was tested by chromatography, 9 of 10 products contained detectable T3 and 5 of 10 contained T4, some delivering daily amounts overlapping ordinary hypothyroidism treatment (Kang 2013). That study did not test this product. Nobody has.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Tiramin actually does
The premise of this entire product line has never been tested on the organ this tablet names, and that is checkable in four citations. The claim the cytamins are sold on is tissue specificity: an extract of organ X preferentially acts on organ X. Four organotypic-culture papers carry that claim. Khavinson 2001 used rat cortex, subcortical structures, liver and thymus. Khavinson 2002 used cortex, subcortical, liver and thymus again, with the matching extracts. Zakutskiĭ 2006 used heart, lung, prostate and pancreas. Ryzhak 2015 used brain cortex, pineal, liver, prostate, thymus, heart and cartilage. Nine tissues across four papers, and not one of them is thyroid.
Why that omission is worse here than it would be elsewhere. The thyroid is not a tissue whose function you argue about. It is a closed feedback loop with three numbers in it — TSH, free T4, free T3 — measured in tens of millions of people a year, and any real effect on the gland shows up in that loop within weeks. Of all seventeen organs on this shelf, this is the one where a positive result would have been easiest to demonstrate and hardest to misattribute. Nobody has demonstrated it.
What the tablet is. A 155 mg pressed tablet of a nucleoprotein fraction from animal thyroid, 40 to a pack, listed by a partner at $45. The vendor publishes no assay: no hormone content, no iodine content, no peptide profile, no source species. For a thyroid preparation those four omissions are not equivalent to the same omissions on a cartilage preparation, and the safety section below is where that difference gets stated.
The mechanism actually on offer. The school's position is regulation of gene expression in the source tissue by short peptides released from the fraction Khavinson 2021, rather than supply of a hormone. Read literally, that predicts a thyroid product should change how the gland behaves without adding thyroxine — which is a strong, specific, falsifiable claim, and one that a single before-and-after thyroid panel would begin to test.
Cell, rodent, human — and where it stops
The literature search, and it returns nothing usable. A PubTator3 query for this product's name, run 8 September 2026, returned two records and neither is about it: a cervical human-papillomavirus detection study from a Romanian county hospital (PMID 17308680) and a 1976 Spanish-language chronic urticaria provocation test (PMID 1035401), both matched on a lexically similar word. A query for the class returns Tokaev 2007, a nutrition review about liver disease. There is no cell study, no animal study and no human study of this tablet. Naming the two false positives rather than reporting a bare zero is deliberate: it lets a reader repeat the search and get the same answer.
One correction to that search, made 9 September 2026. The class term transliterates two ways and the other one is bigger: cytamines returns eleven records where cytamins returns one. Four are about this line: servicemen Khavinson 2001, athletes Emirova 2004, manufacturing Ryzhak 2003 and post-exercise recovery Rozhkova 2007. None of the four measured anything thyroid.
And the human papers widen this page's gap rather than closing it. The 2004 athletics study Emirova 2004 states which cytamins it gave: the liver, pineal and adrenal tablets. So the only product-named human work in the whole line skipped this organ exactly as the explant series did. Two separate choices of which organ to study, made twenty years apart by different groups, and neither picked the one gland whose function is measured tens of millions of times a year. That is a stronger version of the point above, not a weaker one.
The class evidence, and where the thyroid falls out of it. The explant series above reports age-dependent, tissue-matched stimulation of explant growth at 0.01 to 100 ng/ml Ryzhak 2015. Those are real experiments with a real result. They are also a set of nine tissues that excludes this one, so the transfer a reader is invited to make — it worked for liver explants, therefore it works for thyroid — is an assumption about tissue specificity being general, in a product line whose whole selling point is that tissue specificity is particular. The argument cannot be had both ways.
The human rung is empty and the comparison class is not. Thyroid disease is among the most intensively studied areas in endocrinology; levothyroxine is one of the most-prescribed molecules in the world; TSH assays are standardized to third-generation sensitivity. A thyroid product with zero human data is not sitting in a field where data is hard to get. It is sitting in a field where data is cheap and nobody has collected any.
Where it stops, in one line. Everything anybody believes about this tablet is transferred from experiments on other organs, using other preparations, at concentrations applied directly to tissue. There is no thyroid step in the chain at all.
Tiramin pharmacokinetics — how much of it actually gets in
What degrades it. Acid, pepsin, pancreatic proteases and brush-border peptidase hydrolysis, exactly as for any swallowed protein fraction. No enteric coating is claimed, no dissolution data exists, and no analytical method for the preparation has been published, so there is nothing to follow in plasma.
The oral barrier, and the asymmetry that matters for a thyroid product. Thyroid hormones are the exception that proves the point: T4 and T3 are small iodinated amino-acid derivatives that cross the gut wall and are absorbed reliably enough that levothyroxine is given as a tablet. Peptides and nucleoproteins are not. So an oral thyroid preparation has a plausible route to affecting thyroid numbers only if it contains hormone — the thing the manufacturer does not claim it contains and does not assay for. If it contains no hormone, the mechanism has to run through digested peptide fragments, and that is where the arithmetic starts.
The arithmetic, both directions. A 155 mg tablet fully absorbed into 5 liters would be about 31 µg/ml. At 0.1% intact absorption that is 31 ng/ml, still inside the 0.01-100 ng/ml explant band Ryzhak 2015. So a concentration objection is not the honest objection. The honest objection is that the explant band was established on tissues that did not include this one, by applying material directly to the tissue, which no swallowed tablet does.
The comparator route, and why it is not available here. Everywhere else in this school the fallback argument is that the injection of the same extract works and the tablet is a convenience form. No thyroid peptide preparation in this family has ever been injected into anything in the published record, and the parenteral literature that does exist covers brain, thymus and pineal preparations rather than thyroid. This product does not have a stronger sibling to borrow from, which is unusual on the shelf and is worth knowing before buying it.
What would have to be true, and how you would know it was not
Four predictions, and the thyroid axis makes all four cheap.
1. A full thyroid panel before and after a pack. TSH, free T4 and free T3, drawn at the same time of day, before the first tablet and on the day the fortieth is taken. If the regulatory claim is real, TSH is the number that moves and it moves within 6 weeks, because that is the time constant of the pituitary-thyroid feedback loop. Zero published studies of this product have drawn a single one of those three numbers.
2. Against the product: nothing will move, and the mechanism predicts it. A digested protein fraction with no published hormone content has no established route to the thyroid axis, and the tissue-specificity work that underpins the class never included thyroid tissue. Prediction: TSH, free T4 and free T3 unchanged beyond assay variation. This is the falsification that matters, it costs one blood draw, and it is the reason this page exists.
3. The prediction that would be alarming rather than disappointing. If TSH falls and free T4 or free T3 rises after a course, the most likely explanation is not bioregulation — it is that the tablet contains thyroid hormone. That has been documented in a comparable glandular category Kang 2013, and it is the direction of change a buyer should treat as a reason to stop and be evaluated rather than as a result.
4. Thyroid peroxidase antibodies as the specificity control. Anyone with autoimmune thyroid disease is the population most likely to be attracted to a thyroid product and the least likely to get an interpretable result, because TPO antibody status changes what the same TSH means. Draw antibodies at baseline. This is the measurement that separates a reader who can learn something from a course from one who cannot.
What nobody has tested yet
Nobody has run the assay that has already been decisive in a neighboring category. Kang 2013 bought 10 commercially available thyroid supplements and put them through high-performance liquid chromatography. Nine of ten contained detectable T3, at 1.3 to 25.4 micrograms per tablet; five of ten contained T4, at 5.77 to 22.9 micrograms per tablet. At the recommended dose, five delivered more than 10 micrograms of T3 per day and four delivered 8.57 to 91.6 micrograms of T4 per day — amounts the authors describe as capable of producing iatrogenic thyrotoxicosis. That study did not test this product. It is the single most obvious experiment anybody could run on it, and nobody has.
Nobody has closed the tissue-specificity gap. Adding thyroid explants to the organotypic protocol already used for nine other tissues Ryzhak 2015 Zakutskiĭ 2006 would take one experiment in a laboratory that has run this design repeatedly. It would either extend the school's central claim to a tenth organ or expose a limit to it. Either result is publishable and neither has been published.
Nobody has published a course of thyroid function tests around a pack. Not a trial — a case series. Ten people, two panels each, and the human evidence base for this product would go from nothing to something. The barrier is not cost or ethics; it is that nobody has bothered.
Extrapolation, labeled as such. If the fraction really acts by regulating gene expression in thyroid tissue, three things follow that have never been looked for: the effect should be larger in older donors, since that age dependence is the one consistent finding in the explant series; it should be absent in a thyroid that has been surgically removed, which is a clean negative control that exists in the population; and it should not require iodine, which is testable by measuring the tablet's iodine content. None appears in the published record.
Tiramin — its own safety story, not its class's
Three things specific to swallowing an animal thyroid preparation, and the first is the most concrete safety statement on any cytamin page.
Glandular thyroid products have been measured, and most of them contained hormone. Kang 2013 found detectable T3 in 9 of 10 commercially available thyroid supplements and T4 in 5 of 10, with per-tablet content up to 25.4 micrograms of T3 and 22.9 micrograms of T4, and daily deliveries at the labeled dose that overlapped ordinary hypothyroidism treatment. That study tested a different product category and is quoted here as a precedent, not as a finding about this tablet. The precedent is the point: for animal thyroid material, “no hormone is claimed” and “no hormone is present” have repeatedly turned out to be different statements, and no vendor of this product publishes an assay that would tell them apart.
Which makes one symptom pattern worth naming. Palpitations, heat intolerance, unintended weight loss, tremor or new anxiety starting during a course are the presentation of excess thyroid hormone, not of a peptide. In that situation the useful action is a TSH and a free T4 rather than finishing the pack, and it is a situation that becomes considerably more dangerous in anyone with atrial fibrillation, coronary disease or osteoporosis.
And the interaction nobody warns about. Anyone already taking levothyroxine has a dose that was titrated to a TSH. Adding an unassayed thyroid preparation to that is not a supplement decision; it is an uncontrolled change to a titrated drug, and the person most likely to make it is exactly the person for whom the consequences are measurable. There are zero published adverse events for this product because there are zero published studies of it, which is not the same as a clean record.
Sources read for this page
- Khavinson VKh, Cherniak SI, D'iakonov MM. [Cytamines--preparations for maintaining high professional ability and longevity in servicemen]. Voenno-Meditsinskii Zhurnal 2001 [Russian] · PMID 11338817
- Emirova LR, Rozhkova EA, Paniushkin VV, Mirzoian RS, Seifulla NR. [The effects of cytamines and their combinations with ecdystene, apilak, vitamax, and essentiale on the work capability of athletes]. Eksperimental'naia i Klinicheskaia Farmakologiia 2004 [Russian] · PMID 15341074
- Ryzhak GA, Nekrasov PA, Kiselev OI, Khavinson VKh. Study of protein components of natural peptide regulators. Bulletin of Experimental Biology and Medicine 2003 · PMID 12717513
- Rozhkova EA, Ordzhonikidze ZG, Druzhinin AE, Seifulla NR, Paniushkin VV, Kuznetsov IuM. [Using carnosine and natural antioxidants for the prophylaxis of acute post-loading oxidative stress]. Eksperimental'naia i Klinicheskaia Farmakologiia 2007 [Russian] · PMID 18074807
- Kang GY, Parks JR, Fileta B, Chang A, Abdel-Rahim MM, Burch HB, Bernet VJ. Thyroxine and triiodothyronine content in commercially available thyroid health supplements. Thyroid 2013 · PMID 23758055
- Khavinson VK. Tissue-specific effects of peptides. Bulletin of Experimental Biology and Medicine 2001;132(2):807-808 · PMID 11713572
- Khavinson VKh, Malinin VV, Chalisova NI, Grigor'ev EI. [Tissue-specific action of peptides in tissue culture of rats of various ages]. Advances in Gerontology 2002;9:95-100 [Russian] · PMID 12096446
- Zakutskiĭ AN, et al. The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats. Advances in Gerontology 2006 · PMID 17152728
- Ryzhak AP, Chalisova NI, Lin'kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN. [Polypeptides influence on tissue cell cultures regeneration of various age rats]. Advances in Gerontology 2015;28(1):97-103 [Russian] · PMID 26390619
- Tokaev ES. [Bioactive substance used for treatment and preventive maintenance of liver diseases]. Voprosy Pitaniia 2007 [Russian] · PMID 17802767
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
Tiramin — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Tiramin — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Tiramin moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Tiramin in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Tiramin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Tiramin — frequently asked questions
What is Tiramin?
Tiramin (Thyroid cytamin — Khavinson-school organ peptide fraction, oral tablet) is a longevity & bioregulators research compound. A Khavinson-school polypeptide fraction from animal thyroid, 155mg per tablet. The class premise is tissue specificity — an extract of organ X acting on organ X — argued from organotypic explant work at nanogram concentrations. Four papers carry that claim across nine tissues: brain cortex, subcortical structures, pineal, liver, thymus, heart, lung, prostate, pancreas and cartilage. None of them used thyroid.
Where can I find Tiramin dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full Tiramin protocol are available to members inside Skool. This public page covers what Tiramin is, how it works and the evidence.
What is the half-life of Tiramin?
Tiramin has an approximate half-life of Not characterized — no analytical method for this preparation has been published, which is part of what determines how often it's dosed.
What's the evidence behind Tiramin?
Current evidence level: No published study of this product. The literature belongs to the parenteral extracts and the synthetic peptides of the same school.. Tiramin is offered for research purposes only and is not an approved medicine.
What Tiramin is used for
Tiramin appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.